Edition:
United Kingdom

Sartorius Stedim Biotech SA (STDM.PA)

STDM.PA on Paris Stock Exchange

106.70EUR
4:35pm BST
Change (% chg)

€1.80 (+1.72%)
Prev Close
€104.90
Open
€104.90
Day's High
€107.30
Day's Low
€104.80
Volume
32,502
Avg. Vol
53,104
52-wk High
€107.30
52-wk Low
€50.13

Latest Key Developments (Source: Significant Developments)

Sartorius Stedim Biotech Launches New Ambr 250 High Throughput Bioreactor System
Wednesday, 14 Mar 2018 

March 14 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::LAUNCHES NEW AMBR 250 HIGH THROUGHPUT BIOREACTOR SYSTEM FOR PERFUSION CULTURE.  Full Article

Sartorius Stedim Biotech 2017 Underlying EBITDA Up By 2.2%
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH TARGETS CONTINUED PROFITABLE GROWTH - SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025.SALES REVENUE PROJECTED AT AROUND 2.8 BILLION EUROS IN 2025.NEW MEDIUM-TERM TARGETS: UNDERLYING EBITDA MARGIN OF ABOUT 30 PERCENT IN 2025.2017 UNDERLYING EBITDA INCREASED BY 2.2% TO €294.9 MILLION‍​.2017 INCREASE IN SALES REVENUE BY AROUND 4.1% TO EUR 1,081.0 MILLION.FORECASTS A RISE IN SALES REVENUE BY ABOUT 7% TO 10% IN 2018.SEES 2018 INCREASE OF UNDERLYING EBITDA MARGIN BY APPROX. 0.5 PERCENTAGE POINTS OVER PRIOR-YEAR FIGURE..OUTLOOK 2018 CAPEX IS EXPECTED TO BE AT APPROX. 15% OF SALES.  Full Article

Abzena Selects Sartorius Stedim Biotech To Equip Sites In San Diego And Bristol
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::ABZENA SELECTS SARTORIUS STEDIM BIOTECH TO EQUIP US BASED DVLPT AND MANUFACTURING SITES IN SAN DIEGO AND BRISTOL.TO EQUIP ABZENA INTEGRATED CDMO FACILITIES IN BRISTOL AND SAN DIEGO.EQUIP SAN DIEGO PROCESS DVLPT LAB WITH AMBR250, ENABLING FAST SCALE UP TO 500L INITIALLY AND LATER TO 2000L SCALE SINGLE-USE BIOREACTOR.WILL PROVIDE BOTH FACILITIES WITH END-TO-END PROCESS SOLUTIONS IN SINGLE-USE (SU) FORMAT.  Full Article

Sartorius Stedim Biotech 9-month EBITDA up at ‍​216.2 million euros
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::9 MONTHS SALES REVENUE EUR 806.5 ‍​ MILLION VERSUS EUR 785.1 MILLION YEAR AGO.9 MONTHS EBITDA EUR ‍​216.2 MILLION VERSUS EUR 214.1 MILLION YEAR AGO.9 MONTHS NET PROFIT EUR 132.1‍​ MILLION VERSUS EUR 131.3 MILLION YEAR AGO.‍FULL-YEAR 2017 GUIDANCE ADJUSTED, MID-TERM OUTLOOK CONFIRMED​.‍FOR 2017 NOW EXPECTS THAT SALES REVENUE GROWTH WILL REACH APPROX. 4% IN CONSTANT CURRENCIES ​.‍FOR 2017 UNDERLYING EBITDA MARGIN WILL BE APPROX. AT PRIOR-YEAR LEVEL OF 27.5%​.FOR 2017 ‍CAPITAL EXPENDITURES ARE EXPECTED TO BE AT UPPER END OF BANDWIDTH OF AROUND 10% TO 13% OF SALES.​.  Full Article

Sartorius Stedim Biotech cuts 2017 outlook
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::REPORTED ON MONDAY 9-MONTH SALES REVENUE EUR 806 MLN, UP 3.3 PCT IN CONSTANT CURRENCIES.9-MONTH UNDERLYING EBITDA MARGIN AT 26.8 PCT VS 27.3 PCT YEAR AGO.IN 2017 SEES INCREASE OF SALES REVENUE IN CONSTANT CURRENCIES BY ABOUT 4 PCT (VS PREVIOUS GUIDANCE FROM ABOUT 8 PCT TO 12 PCT) .IN 2017 SEES UNDERLYING EBITDA MARGIN IN CONSTANT CURRENCIES AT ABOUT THE PRIOR-YEAR LEVEL OF 27.5 PCT (VS PREVIOUS GUIDANCE ABOUT +0.5 PCT POINTS VS FY 2016).CONFIRMS MID-TERM TARGETS.  Full Article

Sartorius Stedim Biotech 2017 first-half figures
Friday, 21 Jul 2017 

July 21 (Reuters) - SARTORIUS STEDIM BIOTECH SA ::SARTORIUS STEDIM BIOTECH S.A.: 2017 FIRST-HALF FIGURES.H1 SALES EUR 546.7 MILLION VERSUS EUR 508.8 MILLION YEAR AGO.H1 EBITDA EUR 2) 147.4 MILLION VERSUS EUR 136.4 MILLION YEAR AGO.H1 NET PROFIT EUR 89.7 MILLION VERSUS EUR 83.5 MILLION YEAR AGO.SSB CONTINUES TO PROJECT CAPITAL EXPENDITURES OF AROUND 10% TO 13% OF SALES IN CURRENT YEAR..CONFIRMED ITS FULL-YEAR FORECAST FOR 2017.PROJECTS SALES REVENUE TO INCREASE BY ABOUT 8% TO 12%.PROJECTS UNDERLYING EBITDA MARGIN TO RISE BY APPROX. 0.5 PERCENTAGE POINTS OVER PRIOR-YEAR FIGURE OF 27.5%.BOTH FORECASTS GIVEN IN CONSTANT CURRENCIES.  Full Article

Sartorius Stedim Biotech, PACA region and Aix-Marseille Provence Metropolis launch 23 million euros R & D program
Wednesday, 29 Mar 2017 

Sartorius Stedim Biotech Sa : Provence-Alpes-Côte d'Azur region, Aix-Marseille Provence Metropolis and co launch 23 million euros R & D program in Aubagne . Creation of 200 new jobs by the end of 2018 .Sees widening production capacity by one-third and doubling the size of the logistics platform.  Full Article

Sartorius Stedim Biotech proposes to increase dividend by 26 pct
Tuesday, 21 Feb 2017 

Sartorius Stedim Biotech SA :Proposal to annual general shareholders` meeting to increase dividend by 26.0 pct to 0.42 euro ($0.4425) per share.  Full Article

BRIEF-Sartorius Stedim Biotech Net Profit Up at 47.1 Million Euros

* IN Q1 INCREASED ITS SALES REVENUE IN CONSTANT CURRENCIES BY 9.8% (REPORTED 4.6%) TO 281.1 MILLION EUROS.